Abstracts tagged "Epigenetics"

Abstract Number: 2419 • 2012 ACR/ARHP Annual Meeting
Novel Candidate Genes for Structural Foot Disorders: A Genome-Wide Association Study in an Older Caucasian Population
Marian T. Hannan¹, Yi-Hsiang Hsu², Chia Ho Cheng², Youfang Liu³ and Joanne M. Jordan⁴, ¹Institute for Aging Research, Hebrew SeniorLife & Harvard Medical School, Boston, MA, ²Institute for Aging Research, Hebrew SeniorLife & Harvard Med Sch, Boston, MA, ³University of North Carolina, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC
Background/Purpose: Structural foot disorders, such as hallux valgus, deformities of the lesser toes (toes 2-5) and plantar soft-tissue atrophy, commonly affect ~ 60% of older…
Abstract Number: 2332 • 2012 ACR/ARHP Annual Meeting
Suppression of PP2Ac Causes DNA Hypermethylation Through Enhanced Pmek/Perk Activity in T Cells
Katsue S. Watanabe¹, Kamalpreet Nagpal² and George C. Tsokos³, ¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Background/Purpose: Although many reports have focused on the impaired MEK-ERK signaling pathway in T cells from systemic lupus erythematosus (SLE) patients which results in suppression…
Abstract Number: 2317 • 2012 ACR/ARHP Annual Meeting
Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression in CD4+ T Cells
Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, Internal Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: CD4+CD28- T cells are enriched in chronic inflammatory diseases like rheumatoid arthritis (RA) and lupus. They are cytotoxic and resistant to apoptosis. Compared to…
Abstract Number: 2285 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus RNA-Seq: Endogenous Retroviral Group K Overexpression in Monocytes
Lihua Shi¹, Zhe Zhang², Michelle Petri³ and Kate Sullivan⁴, ¹Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Bioinformatics, Bioinformatics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Gene expression studies of peripheral blood mononuclear cells in SLE have consistently shown an interferon signature. We previously examined monocytes from SLE patients to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.